article thumbnail

Small Molecule Apis: Aligning Drug Strategy with Partnering Strategy A Review of the Trends and Market Dynamics Driving Outsourcing Decisions

PharmaTech

With hundreds of potential partners that drug owners can choose from to develop and manufacture small molecule APIs, choosing the best partner can be a challenging task. In this white paper, we explore the importance of purposefully aligning the overall drug development strategy with a partnering strategy.

article thumbnail

Six Trends to Watch in the New Healthcare Economy

Drug Channels

Karen examines trends in drug development, pricing, and healthcare. To learn more, download Six trends and tactics to thrive in the new healthcare economy , a free white paper from Wolters Kluwer. She also serves as co-chair of Maintenance and Control at the NCPDP. Read on for Karen’s insights.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

MD Anderson and Xilis partner to expedite new cancer therapies development

Pharmaceutical Technology

It may offer opportunities for third-party collaborations to guide the new cell therapies and drugs development, if successful. It enables quick evaluation of a patient tumour response to a range of cancer drug modalities within 14 days of obtaining harvested samples of tumour cells.

article thumbnail

AbbVie and Capsida partner for gene therapies to treat eye diseases

Pharmaceutical Technology

Combining AbbVie’s expertise in eye disease drug development and commercialisation with Capsida’s fully integrated next-generation AAV engineering platform and manufacturing capabilities offers the potential to provide novel therapies enabling unprecedented benefit to patients with serious eye diseases.”

article thumbnail

Solid Biosciences partners with Phlox for cardiac disease therapies

Pharmaceutical Technology

Under the research partnership deal, the companies will develop new precision genetic medicines for a severe form of genetic dilated cardiomyopathy (DCM). Solid Biosciences stated that the partnership boosts its scientific capabilities along with commercial potential in cardiac therapy.

article thumbnail

10 Effective and Affordable Marketing Networking Strategies for Pharma Professionals in 2025

Pharma Marketing Network

From discussions on branded drug developments to sessions hosted by major players like Pfizer and Novartis , there’s always something to learn. Whether it’s with academic institutions or industry colleagues, collaborating on white papers or case studies can have long-lasting benefits.

article thumbnail

FDA suggests ways to curb constraints with rare disease gene therapy trials

Pharmaceutical Technology

Despite the challenges that drug developers must overcome to produce gene therapies for rare diseases, Hart underscored the FDA’s intent to encourage more innovation in this space. “We Therefore, the good news is we have flexibilities that can be offered to see drug development for these diseases.”